Financings in Brief: Anika Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics: Hyaluronic acid product firm grosses $17.5 mil. from a secondary offering of 3 mil. shares at $7 each, 2.5 mil. offered by the company and 500,000 by selling shareholders. Proceeds will be used to expand manufacturing capacity, fund R&D and "for working capital and other general corporate purposes" ("The Gray Sheet" Nov. 10, p. 10). Managers of the offering were Furman Selz, Volpe Brown Whelan & Co. and Leerink, Swann & Co...